The purpose of this pilot trial, Transitioning to Adult Care (TRANSIT), is to develop and test an intervention (i.e., a standardized, tailored transition program focused on enhancing adherence) to improve outcomes for emerging adults who underwent heart transplantation as children and transfer to adult care.
To determine the ability of established and novel cardiac biomarkers to predict short- and long-term outcomes.
The purpose of this study is to determine the clinical outcomes of sensitized pediatric heart transplant recipients with a positive donor-specific cytotoxicity cross-match and to compare them with outcomes in nonsensitized heart transplant recipients.
To determine outcomes following ABO incompatible pediatric heart transplants.
Prospective cohort study of pediatric cases of DCM, HCM, and RCM aiming to identify new disease-causing and disease-associated mutations as well as geno-phenotypes cardiomyopathy.
The investigator's primary goal is to quantitatively detect donor-specific DNA in plasma of organ transplant recipients. The investigator believe's that donor specific DNA can be isolated and quantified from transplant recipient serum. The investigator hypothesizes that the percent level of donor DNA circulating in recipient serum will reflect transplant rejection.
The HeartMate III Left Ventricular Assist System (LVAS) is a prospective, multi-center, study comparing the HeartMate III LVAS to the HeartMate II® LVAS in advanced stage heart failure patients. The study will be conducted as a staged pivotal study that includes a pre-specified early assessment for safety. Researchers at up to 60 centers will evaluate the device for use as long-term support for patients who are not candidates for cardiac transplant (also known as Destination Therapy).